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1. Introduction
Since the invention of the microscope over 300 years
ago, light has been used to probe biological samples.
With the appearance of laser sources, versatile detec-
tors (e.g., photomultipliers and CCD arrays), and opti-
cal filters, the use of light in biological and medical
research has become increasingly sophisticated. The
interaction between light and biological system leads to
the modification of both; unraveling and understanding
the changes is the purview of biophotonics [1]. The
scope of biophotonic applications can be gleaned from
the large number of examples described in recent books
edited by Marriott and Parker [2,3].
To discuss diagnostic tools it is useful to have a clear
picture of what is being measured. On the most funda-
mental level, each cell has a fixed content of deoxyri-
bonucleic acid (DNA) (genome) and a certain content
of proteins (proteome). As currently understood, most
functions of the cell are reflected in the genes that are
activated, the amount of proteins expressed, and post
transcription modifications that occur. Thus the mean-
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In order to maintain the rapid advance of
biophotonics in the U.S. and enhance our
competitiveness worldwide, key measure-
ment tools must be in place. As part of a
wide-reaching effort to improve the U.S.
technology base, the National Institute of
Standards and Technology sponsored a
workshop titled “Biophotonic tools for cell
and tissue diagnostics.” The workshop
focused on diagnostic techniques involv-
ing the interaction between biological sys-
tems and photons. Through invited presen-
tations by industry representatives and
panel discussion, near- and far-term meas-
urement needs were evaluated. As a result
of this workshop, this document has been
prepared on the measurement tools needed
for biophotonic cell and tissue diagnostics.
This will become a part of the larger
measurement road-mapping effort to be
presented to the Nation as an assessment
of the U.S. Measurement System. The
information will be used to highlight
measurement needs to the community and
to facilitate solutions.
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ingful measurements for elucidating the detailed state
of a cell are the number and type of genes being
expressed, and the proteins that are present in the cell.
Normal cells are associated with certain characteristic
levels and patterns of gene transcription and certain
characteristic levels of proteins. Disease states are asso-
ciated with deviations from these “normal” levels and
patterns. The measurement technologies which attempt
to give a detailed picture of the genome and proteome
are based on microarrays for DNA and proteins. With
the development of microarrays there is an expectation
that more detailed knowledge of gene expression and
protein content can be obtained for diagnostic purpos-
es. For example, patterns of gene expression arrays are
useful in differentiating myeloid from lymphoid
leukemia. They are even more useful in the classifica-
tion of heterogeneous lymphoid neoplasmas that cannot
be resolved with conventional morphology analysis.
Much of current biological research is aimed at
obtaining a detailed understanding of the various path-
ways in the cell that are associated with normal func-
tions. This research often identifies characteristic genes
and proteins associated with a particular function of the
cell. Consequently, it also becomes possible to identify
genes and proteins associated with malfunctions. These
genes and proteins then can serve as “surrogate mark-
ers” for a pathological condition at an early, preclinical
stage in the development of diseases. The measurement
of such biomarkers constitutes a diagnostic assay. A
classical example is the measurement of the absolute
number of CD4 T cells, CD8 T cells and CD20 B cells
based on cell surface antigens in whole blood. The
decrease of the CD4/CD8 ratio is associated with HIV
disease and an increase in CD20 positive B cells is
observed in occurrences of lymphoid leukemia. These
measurements are performed on single lymph cells
using flow cytometers.
Once a pathological condition has established itself
in the body, larger scale (tissue level) abnormalities
appear. Traditionally, the detection of deviations in tis-
sue biochemistry has been performed in histology labs,
which use microscopes to look at cell morphology and
histopathology in biopsy samples. Thus it is possible to
detect the presence of tumors, deterioration of artery
walls, abnormal growth in neuron sheaths, and other
examples. Improvements in image acquisition and
analysis have resulted in significant increase in the
accuracy of disease detection using the traditional tech-
niques.
The development of optical coherence tomography
shows promise for improvement in the detection of
subtle morphological changes in vivo [4], and thus
speed the detection of disease conditions. Similar
expectations have fueled the development of novel in
situ detection techniques, based on measurement of
intrinsic spectroscopic properties in skin and surface
layers of tissue such as fluorescence lifetime imaging,
multiphoton imaging, hyperspectral imaging, and sin-
gle molecule detection. Many of the new techniques are
in clinical testing and are expected to be used in the
future.
The remaining sections of this paper highlight the
major measurement challenges that currently limit the
usefulness of four common diagnostic techniques
involving the interaction of light and biological sys-
tems. These four techniques are: Microarrays, Flow
Cytometry, Optical Microscopy, and Optical Coherence
Tomography. In each section, there are suggested
approaches to overcoming these obstacles.
2. Measurement Tools and Challenges
2.1 Microarrays
The diversity of test sequences and well behaved tar-
get/probe interactions of genes allow the design of fully
informative assays, based on microarray techniques.
Consequently, microarrays have been widely employed
as tools to study the role of rare genes (DNA and
ribonucleic acid (RNA)) in human diseases, infectious
pathogens, and microbes. However, the dearth of
microarrays that have been approved by the Food and
Drug Administration (FDA) has hindered the use of
microarrays as clinical diagnostic tools. The microarray
technology is capable of examining thousands of differ-
ent genes from a single small tissue sample to deter-
mine genomic characteristics, for instance, to differen-
tiate between mutated and normal genes. Diagnostic
microarrays often contain synthesized DNA sequences
on the grid points of a glass slide. The sequences are
then hybridized with genomic DNA from the individual
patient to determine to which allelic sequences it binds,
and therefore which alleles are present in the patient’s
genome. An excellent overview of the microarray tech-
nology is provided in a recent report [5].
Reliable detection of single pathogenic species and
rare transcripts are becoming feasible. Further enhance-
ment of microarray techniques will allow us to look at
many targets in parallel, for rapid diagnosis and effec-
tive response to infectious diseases, naturally occurring
epidemics, and bioterrorist attacks. For instance, the
containment of water- and food-borne infections is pos-
sible by effective identification of the causes of the
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infections. In battling against rapidly spreading infec-
tious diseases, the misuse of antibiotics and the lack of
incentives to develop new antibiotic and antiviral
agents have increased the risk of more serious infec-
tions. The ability to differentiate the origins and types
of infections will enable rational and highly targeted
drug therapy.
Whether the analyte is microbial or human genomic
DNA, the objective is to reliably detect as few as one
and as many as 100,000 specific DNA or RNA mole-
cules in biological samples. The ideal assay would be
fast (real time), specific, sensitive, quantitative, flexi-
ble, able to detect many genes in parallel, portable and
robust, and inexpensive. Among other gene detection
methods, many Polymerase Chain Reaction (PCR)-
related techniques have been gradually adopted by clin-
ical laboratories, while array-based assays are still lag-
ging behind because of the hurdles associated with
gaining FDA approval. Currently, there are only a few
FDA-approved microarray-based assays. One example
is a technique for determining single nucleotide poly-
morphisms in drug metabolizing (P450) enzymes.
Some of the factors contributing to the limited number
of FDA-approved of microarray-based assays are listed
below.
2.1.1 The Identification of Rare Genes From
Clinical and Environmental Isolates to
Define Clinically Relevant Templates for
Microarrays
Problem:
To detect rare genes and pathogens (ultimately at the
single copy level), the sensitivity and accuracy of the
detection needs to be improved to overcome current
limitations. One of the major hurdles is undesirable
optical properties of fluorescent probes, such as
monoreactive dyes, which place limits on the sensitivi-
ty and quantitation. Their relatively limited dynamic
range and unstable fluorescence emission cause serious
inaccuracy in parallel assays to detect multiple genes
and pathogens on one microarray template.
Approach:
In addition to the development of optical standards
involving conventional organic fluorescence probes,
other standards employing novel fluorescent probes
have also been proposed and are under development to
enhance sensitivity, accuracy, and speed of the tech-
nique. Fluorescent nanocrystals, nanoshells, and nano-
tubes have been identified to have unique optical and
physical properties that overcome the limitations of
conventional fluorescent probes. For instance, semi-
conductor fluorescent nanocrystals (NCs) and quantum
dots (QDs) exhibit long fluorescence lifetimes, narrow
emission spectra, and are not susceptible to pho-
todegradation. QDs not only exhibit higher fluores-
cence quantum yields than organic dyes, but their
longer fluorescence lifetime allows temporal “gating”
with respect to background autofluorescence, which
enhances the contrast in biological imaging and sensing
applications. Only a few nanometers in diameter, QDs
are usually composed of a semiconductor core (e.g.,
CdSe, InP, ZnSe, etc.) capped with a ZnS shell. QDs
fluoresce with very broad absorption and narrow emis-
sion spectra. By adjusting the core size, the emission
wavelength can be finely tuned. The ZnS shell helps in
stabilizing the core, makes the light emission more
intense, and keeps the QD from degrading. For biolog-
ical application, it has been demonstrated that the sur-
faces of NCs can be conjugated with functional groups
and molecules, so they can be readily linked to specif-
ic DNA sequences for use in microarray platforms. The
excellent photochemical and physical properties of
QDs and NCs would be excellent surrogates to organic
dyes, enabling highly sensitive and quantitative meas-
urements in microarray techniques.
2.1.2 Dearth of Validation Standards for Clinical
Applications
Problem:
For the validation of screening methods for clinical
applications of this technique, standards to correlate
between clinical diagnostics and screening results need
to be established. There is no standard infrastructure or
protocol to establish and validate clinically relevant
genomic templates for the detection of rare genes. In
addition, no validation standards of screening methods
for such clinical samples exist. Rapid validation of
screening methods and templates to establish clinically
applicable assays is of urgent need. According to a
recent FDA workshop on microarray techniques [6],
FDA’s Critical Path Initiative [7] identifies pharma-
cogenomics as a key opportunity in advancing medical
product development and personalized medicine. The
FDA issued the “Guidance for Industry:
Pharmacogenomic Data Submissions” [8] to facilitate
scientific progress in the field of pharmacogenomics
and to facilitate the use of pharmacogenomic data in
drug development and medical diagnostics. In this
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guidance, it is identified that exploratory genomic data
obtained with microarrays represent one of the core
competences in pharmacogenomics; however, this
workshop also identified that quantitative flow cytom-
etry applications will be limited until inter-laboratory
variability can be controlled and standards are identi-
fied [9].
Approach:
To accelerate this technique towards broader applica-
tions including clinical diagnostics, validation tech-
niques in screening gene chip templates for clinical
applications and standards to correlate between clinical
diagnostics and screening results are needed. To this
end, a set of techniques to enable high throughput and
high accuracy measurements in relevant fields such as
optical characterization of conventional and novel
probes and quantitative assessment of clinically rele-
vant gene chip templates needs to be identified and
established. A strong research partnership among clini-
cal institutes, government agencies, and other research
parties will be central for this purpose. This multi-
agency partnership may also solve other challenges
including high instrumentation cost, lack of interoper-
ability of equipment, early phase clinical trials, and
obtaining FDA approvals.
2.1.3 Need for More Rapid, Effective Sample
Preparation
Problem:
The goal of sample preparation methods is to effec-
tively isolate, extract, and concentrate samples ade-
quate for the microarray analysis. Sample preparation
is challenging and is still one of the more time-consum-
ing, labor-intensive, and error-prone steps in the analyt-
ical cycle. Specimens are often complex matrices that
bind or mask target analytes and contain interfering
substances. There is a pressing need to minimize these
errors especially with highly parallel assays.
Approach:
Sampling errors can be minimized by adequately
training technicians to use sophisticated biochemical
methods and by incorporating consistent automated
procedures. Sample integrity can also be validated by
the use of appropriate controls including standard tem-
plates and test samples. A promising new approach is to
implement biological MicroElectroMechanical systems
(bioMEMS) for systematic sample preparation and
analysis in a highly controlled manner. The bioMEMS-
based technique is rapidly evolving and may allow
effective sample preparation for the conventional
microarray platform. In addition, bioMEMS may lead
to a fully integrated single lab-on-a-chip platform
including sample preparation, hybridization, and final-
ly the detection.
2.2 Flow Cytometry
Flow cytometers measure laser induced fluorescence
and light scattering from individual cells passing
through a focused laser beam. Immunofluorescence
analysis is one of the most common applications. Prior
to the flow cytometer measurements, cells are incubat-
ed in a solution which contains a selection of antibod-
ies with attached fluorophore labels. The antibodies
react with specific antigens on the surface of the cell
and the attached fluorophores serve as indicators of the
antibodies which are present on the cell surface. A
recent trend has been toward simultaneous measure-
ment of multiple fluorophore colors each indicating the
presence of a specific antigen on the cell surface. The
importance of determining the actual number of anti-
gens on the surface of the cell has driven the need for
quantitation in flow cytometry [10].
For most biological applications, cell to cell variabil-
ity in the quantity being measured using flow cytome-
try methods is relatively large (> 10 %). These quanti-
ties include, but are not limited to, cell volume, cell pig-
ment, membrane fluidity, as well as the amounts of
RNA, antigens, and DNA. The exception is the amount
of DNA per cell, which in normal, non-replicating cells
is constant. Practical measurements of DNA content
per cell must have standard uncertainty of 3 % or bet-
ter. In many other (non-DNA) applications, the amount
of a cellular material being measured can vary over a
range of three decades or more within a heterogeneous
population.
Flow cytometer signals are pulses typically at rates
up to 50,000 Hz with durations of 1 to 10 µs, and which
produce 0 to 107 photons per pulse. The fundamental
measurement is the total (integrated) number of pho-
tons (or photoelectrons) in the pulse.
2.2.1 Lack of Linear Measurement Response
Problem:
Accuracy in flow cytometry measurements is syn-
onymous with linearity or proportionality. A typical
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immunofluorescence application can require a meas-
urement range of four decades. To provide for the vari-
ous types of applications an instrument might
encounter, an instrument must be capable of measure-
ments over more than six decades. However, linearity
over a six decade measurement range is also desirable
in a multi-purpose tool. Usually the readout range is
limited to four decades by the data acquisition electron-
ics, therefore a portion of the six decade span must be
selected. Photomultiplier tubes (PMTs) provide flexible
and nearly noise-free gain, and the ability to select the
optical (photon) range that will be measured, but PMTs
are not perfectly linear detectors over their entire oper-
ational range. The four decade range that the data
acquisition electronics must cover is also a challenge,
addressed either by the use of logarithmic amplifiers or
by using linear amplifiers with 14-bit or greater A/D
converters.
For a general purpose flow cytometer, accuracy of
1 % or better is desirable. To achieve that accuracy, the
nonlinear response must be less than a few percent. The
two situations requiring the greatest linearity are meas-
urements of DNA content per cell and correction for
spectral overlap of different fluorophores in different
detector channels. The stringent requirement for linear-
ity in spectral overlap correction may not be immedi-
ately obvious. But in practice, the overlap correction
uses linear equations that can involve the subtraction of
large numbers. Considering that the data can cover 4
decades, small errors in the large numbers can result in
a large absolute error in the subtracted result.
Approach:
The best method for characterizing linearity has been
to use a double pulse method which uses two input sig-
nals of constant ratio but varying absolute value to
measure deviation from linearity. For a perfectly linear
system, the ratio of the measured values will be con-
stant over the entire signal range. Deviation from lin-
earity can be measured relative to an average value. A
practical alternative is to analyze a mixture of particles
with known relative intensity values and compare the
measurement with expected result.
2.2.2 Standards for Quantitation of Fluorescence
Intensity and Specific Cellular Material
Problem:
A fluorescence intensity standard is most useful
when its emission spectrum matches a fluorophore used
to stain cells. In that case a standard measure of fluores-
cence production known as molecules of equivalent
soluble fluorophore (MESF) can be used. Using a spec-
trally matched standard and fluorophore of interest
insures that spectral variations in optical filters and
other optical components do not affect the intensity
standardization process. NIST provides a set of fluores-
cein isothiocyanate (FITC) labeled beads, RM 8640,
which is the only nationally recognized fluorescent par-
ticle reference material [11]. Several companies pro-
vide fluorescent particle intensity standards for other
fluorophores, but they are not recognized by any stan-
dards setting body.
Approach:
A possible approach is to develop internally consis-
tent systems for quantitating the amount of antibody
bound per cell using highly characterized fluorescent
antibodies and spectrally matched particle standards.
But this is only widely done for the fluorochrome phy-
coerythrin. Presently the only reliable standards for
quantitating other cellular components use biological
standards. An example of this is the cell nuclei from a
defined species as a standard for DNA content.
2.2.3 Effect of Instrument Limitations on Particle
Fluorescence Measurements
Problem:
To make precise flow cytometry measurements, one
must overcome instrument limitations due to variabili-
ty at the component level. The sample sizes, ranging
from thousands to millions of particles, compound the
variability problem. The most common applications
require resolving subpopulations of particles based on
differences in their average fluorescence intensity.
Ideally, the measurement process variability is signifi-
cantly less than the variability in the sample itself.
Since the signal can range over 4 decades or more,
measurement uncertainty is limited by different factors
(e.g., illumination uniformity, photoelectron statistics,
background light, electronic noise) in different regions
of signal level. This complicates standardizing or char-
acterizing the uncertainty of measurements.
Approach:
As a practical way to characterize measurement vari-
ability over a wide range of light intensities, a set of
particles stained with different amounts of fluorescent
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dye and with known intrinsic (sample) variances can be
analyzed. The increase in measured coefficient of vari-
ation (CV) above the known sample CV of each type of
particle allows the instrument contribution to CV or
variance to be determined at different signal levels.
With just a few carefully chosen particle intensities
(dim, midlevel and bright on the measurement scale), it
is possible to separately determine electronic noise,
background light, photoelectron statistics, and illumi-
nation uniformity contributions to the measurement
variance over the entire 4 decade signal range.
Determining intrinsic sample CV within appropriate
limits takes a great deal of care and is most difficult for
brightly fluorescent particles with intrinsic CV’s less
than 1 %.
2.3 Optical Microscopy
Optical microscopy has been a staple of biological
research since Leeuwenhoek demonstrated its utility in
1674. In contrast to cytometers or microarrays,
described above, optical microscopy provides images
of biological specimens, ranging from tissue samples,
at low magnifications, to images within single cells, at
high magnifications. With the advent of multispectral
imaging and specific biological labels, more sophisti-
cated optical microscopy techniques are moving
beyond the realm of simply providing records of tissue
structure and morphology and into the realm of provid-
ing quantitative data regarding tissue behavior. These
techniques take advantage of the spectral distribution of
the optical illumination and how these different spectral
components interact with biological tissues and labels.
However, even when used to classify tissue samples,
and certainly when used to provide enhanced scientific
understanding or medical diagnostics, a number of
measurement and procedural needs exist, the lack of
which can result in image misinterpretation. These
needs can conveniently be broken into four categories:
hardware, reagents, software, and human involvement. 
2.3.1 Hardware
2.3.1.1 Hardware Barriers to Acquiring Accurate
Spectral Images
Problem:
Variations in detector gain [12,13], for example,
spectral dependence or nonlinear intensity response,
distort images by inaccurately representing analyte
concentrations for both single analytes and for compar-
ison between analyte concentrations. In a similar fash-
ion, misaligned optical components reduce sensitivity
and resolution, resulting in decreased contrast and
broadened analyte locations in images.
Approach:
Detector and system alignment problems have long
been recognized and there are standard procedures to
address most of them. Almost all commercial optical
instruments are provided with detailed alignment
instructions. Routine maintenance, e.g., a weekly align-
ment check and detector calibration with either a multi-
line lamp or multi-wavelength fluorescence standard
can minimize alignment and wavelength sensitivity
issues. Similarly, detector calibration as a function of
intensity, using a calibrated light source [14] can solve
the nonlinear detector gain problem. However, difficul-
ties remain with these solutions. Whereas routine cali-
bration procedures will detect temporal degradation of
the detector and the optical elements in the light path of
the instrument, assuming the presence of stable optical
standards, it becomes difficult to maintain the instru-
mentation if aging of the standards has to be incorpo-
rated into the calibration procedure. To counter this
problem, it is necessary for the user to have access to
traceable standards with a guaranteed lifetime under
prescribed storage conditions. Additionally, the stan-
dards need to be routinely re-certified [15,16] in a time-
frame corresponding to minimum standard degrada-
tion. Such timeframes will almost certainly have to be
determined empirically, since usage patterns, storage
conditions, and environmental parameters will all con-
tribute to degradation rates.
Even with appropriate standards and well defined
calibration procedures, there remains at least one fur-
ther problem in assuring accuracy associated with com-
paring images obtained on different instruments. Each
instrument will have its own limitations. Therefore
comparisons between images obtained on different
instruments require a thorough understanding of the
limitations associated with the specific instruments
being used to generate the images.
2.3.1.2 Degradation of Optical Components
Problem:
The problem of time dependent degradation has been
alluded to above. It is important for the user to bear in
mind that, in addition to the detector, all optical compo-
nents degrade with time (filters, lenses, mirrors) due to
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atmospheric attack on the optical coatings [17]. While
this is usually a slow process, occurring over years, it
affects image quality and accuracy and, because it is
gradual, there is no standard procedure dictating when
components should be replaced or recoated.
Approach:
Temporal degradation of optical components can be
monitored through routine, e.g., monthly or bi-month-
ly, component inspection using a standard source and a
calibrated detector.
2.3.2 Reagents and Labels
Problem:
Probes, such as antibodies, peptides, and nucleic
acids, all of which are either naturally occurring or arti-
ficially engineered, interact with specific substances
within a cell or within tissues [18]. Labeled probes
allow detection of specific proteins, chemical reactions,
and even time dependent interactions. Consequently,
probes have to meet the following conditions: high
specificity, high affinity, and appropriate mobility.
However, with higher specificity, the number of
required probes that are needed to completely assess
tissue behavior is greatly increased. Indeed, to obtain
more detailed and more specific information regarding
tissue response, it is becoming necessary to use multi-
ple probes, each of which exhibits high specificity and
high affinity and all of which have mobilities that allow
them to concurrently interact with their tissue counter-
parts.
Labels are the components attached to probes that
allow probe tracking and imaging. They can be radioac-
tive, magnetic, or fluorescent, and they can be a natural
part of the probe or either a biological or non-biologi-
cal element attached to the probe. For optical imaging,
labels are typically organic [19] or inorganic [20] fluo-
rophores. Regardless of their source, all labels must
address the following issues: spectral stability (both
intensity and spectral behavior), quenching, toxicity,
and mobility [21]. Clearly, the spectral behavior has to
be stable; however the environment within tissue is
extremely aggressive and can result in chemical attack
on the labels destroying or distorting their fluorescence.
Fluorescence quenching can occur through multiple
paths: photobleaching, proximity to other similar fluo-
rescent sources, or fluorescent resonance energy trans-
fer (FRET). Toxicity is a matter of concern for all in
vivo and most in vitro applications [22]. Currently,
there is very little understanding of the possible toxici-
ty issues regarding labels, which are typically sub-
micrometer size. However, not only does toxicity
increase as particle size decreases, but the toxicity of a
particle is also a function of shape, deformability, and
stability. As labels increase the overall size of the
probes, they exacerbate the mobility issues associated
with movement of the probe to reaction sites. Finally,
the fluorescent output of labels can be confused with
naturally occurring fluorescence from other sources
that have no relation to the biological component or
reaction of interest.
Approach:
There is a great deal of ongoing research to address
the problems listed above [23]. At this time, no clear,
across-the-board solutions have been found. Rather,
tradeoffs between the benefits and problems associated
with possible solutions must be weighed. For example,
probes are being engineered to achieve high specificity
and affinity. The ability of the probe to move through
the cell or tissue to reaction sites depends upon its size
and deformability as well as upon the properties of any
attached labels in addition to the specificity already
mentioned. However, increased specificity may lead to
an increase in the number of probes required to identi-
fy suspect tissues and/or cells. There is also the ques-
tion of toxicity. In general, organic fluorophores, partic-
ularly those developed from naturally occurring biolog-
ical processes, are considered safer than inorganic flu-
orophores such as quantum dots (QDs), which are alien
to biological systems and frequently are composed of
toxic elements. However, QDs have far greater bright-
ness and are less prone to photo-bleaching and quench-
ing. Because the optical properties of QDs are con-
trolled by their size, QDs that fluoresce at specific
wavelengths can be developed far more rapidly than
organic fluorophores can be developed. Understanding
of the effect of QDs on probe mobility in biological
systems is currently lacking. Unlike organic molecules,
QDs cannot deform to allow migration through con-
stricted regions and, because the QD fluorescence
wavelength is a function of size, mobility considera-
tions may ultimately restrict the wavelength range for
various applications. Nevertheless, QDs overcome
some of the most serious problems associated with
development of organic fluorophores as labels and are
being used both in vitro and in small animal studied.
Toxicity concerns will prevent their use in vivo in
human subjects in the immediate future.
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2.3.3 Software
2.3.3.1 Linear Unmixing
Problem:
Linear unmixing is the process by which multispec-
tral contributions to an image pixel are separated into
their individual source component contributions. The
assumption underlying linear unmixing is that the total
signal at any given image pixel is a linear combination
[24] of the light signals (i.e., fluorescence sources or
chromogen absorbance) plus an error term. The error
term includes both the contribution due to noise and
uncertainty resulting from imprecise or erroneous fit-
ting criteria. While it is not required that either the
number or the shapes of the individual spectra be
known a priori, tools exist that can infer the source val-
ues from the set of image pixels – the uncertainty com-
ponent varies with the statistical approach used to
unmix the data [25] and to a greater extent, with the
accuracy and completeness of the spectral endmembers
(spectral libraries) used in the unmixing. Such varia-
tions alter the quantitative attribution of the image pixel
intensities to the individual signals. The unmixing algo-
rithms themselves are well understood and validated,
being based on years of non-imaging spectroscopic
analytical techniques, but accurate results depend on
having optically well-behaved samples (scattering and
stray light, for example, can introduce errors) as well as
correct spectral endmembers. Methods for creating
appropriate spectral libraries vary from the trivial (sim-
ply sampling spectra of pure fluorophores or chro-
mogens) to the complex, e.g., multiple curve resolution
[26]. As with any involved scientific method, appropri-
ate validation strategies are essential to its successful
employment.
Approach:
However the libraries are generated, the performance
of the spectral unmixing method used, namely, the
combination of library and algorithm, should be appro-
priately validated using control samples and/or well-
characterized mixtures of labels. The usual standards of
the scientific method, if applied properly, should facil-
itate this process. However, widespread discussion of
the details of the mathematics involved (e.g., the use of
non-negativity constraints) is probably not necessary;
what is more relevant is the performance of conceiv-
ably proprietary strategies on publicly available stan-
dard samples. Appropriate protocols or guidelines of a
general nature that could be used by method developers
to work up and test each new combination of sample
preparation and unmixing parameters can put these
techniques on solid ground. Workshops to address
method development and assessment with participation
from researchers, image processing software manufac-
turers, and end users would be useful. Subsequent
incorporation of these guidelines into commercial soft-
ware is essential.
2.3.3.2 Confounding Phenomena
Problem:
Experimental aspects of confounding phenomena,
for example, autofluorescence, noise, photobleaching,
quenching, fluorescence resonance energy transfer,
etc., have been discussed previously. The potential for
interactions between measured signals and sample
properties (scattering, absorbance, variable thickness,
etc.) also need to be acknowledged. Finally, it is worth
mentioning that the entire sample procurement, pro-
cessing and labeling process is fraught with potential
problems. Attempts have been made to address these
problems through software development. There are two
concerns with this approach: software limitations and
operator education. Experimental procedures exist that
will identify and, in some cases, compensate for most
confounding phenomena. However, data acquisition
and analysis software must be flexible enough to allow
these procedures and operators must be educated in
proper techniques both in recording the data and in sub-
sequent analysis.
Approach:
One particularly useful approach is to include image
diagnostics into the analysis software that could con-
ceivably look for signatures of some of the problems
noted above. For example, with linear unmixing, one
can monitor the magnitude of the fitting error at every
pixel; if it exceeds a certain threshold, that could be an
indication that something is wrong either with the sam-
ple, the imaging, or the unmixing method. Similar tools
could exist to monitor other confounding phenomena.
Appropriate correction techniques can be applied.
These could include noise filters, intensity scaling
capability, image comparison and subtraction tools, and
wavelength discrimination capacity. This collection of
tools will permit background noise reduction, autofluo-
rescence detection and possible subtraction, and hyper-
spectral monitoring (see linear unmixing, above).
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These tools exist in many image analysis software
packages. However, appropriate procedures need to be
followed so that inappropriate use of powerful image
processing techniques do not distort the data.
A discussion of the Food and Drug Administration
(FDA) guidelines for software validity and traceability
can be found on the FDA web site [27]. A critical con-
cept emphasized in the document is that software can-
not be validated in the absence of instrumentation. All
possible hardware and software procedure combina-
tions must be tested before software can be considered
validated. In the context of this document, a similar
conclusion can be drawn; software must be flexible
enough to allow any necessary procedure to identify
and minimize the presence of artifacts. Moreover, soft-
ware documentation should be adequate to provide the
user information regarding artifact detection and possi-
ble generation as a result of specific image processing
steps. However, the user has the responsibility of
understanding the implications of image analysis steps,
regardless of documentation in the software. Such
understanding would derive automatically from stan-
dardization of image processing procedures for specif-
ic biological applications.
2.3.4 Human Involvement
In the present, and for the foreseeable future, human
participation in medical image analysis is unavoidable.
This is due, in part, to the fact that medical imaging is
undergoing rapid advances that currently preclude
complete automation, in part because computer algo-
rithms are not yet as sensitive to optical patterns as the
human brain, and, in part because of reluctance for
relinquishing control and legal responsibility of such a
complicated task to an automated system. However,
incorporation of the human mind into image analysis
simultaneously incorporates biases that can distort the
analysis. It should be noted that solutions to this prob-
lem are not independent of the solutions to the hard-
ware data acquisition and software image analysis
issues discussed above.
2.3.4.1 If a Pattern is Expected and Observed, It
is Assumed to be True
Problem:
The process of seeing what is expected and, conse-
quently, forgoing critical assessment, is an universal
hazard in research activities. This danger is particularly
present in image appraisals for two reasons. First, the
human mind has evolved to identify patterns, even
when obscured by noisy optical backgrounds. The exis-
tence of similarly appearing objects in proximity to
each other, or with a distribution that evokes a (partial-
ly complete) geometric structure, or even in a pattern
that appears to contain symmetry elements can lead the
mind to interpret patterns that do not exist in the data.
Second, images, unlike graphs or charts, cannot contain
quantitative uncertainty values conveniently attached
to the data. If the image appears to support the expect-
ed model, there is a tendency to avoid searching for
artifacts or errors.
Approach:
With the exception of using completely automated
image analysis, there is no guaranteed solution to this
problem. Training human operators in potential sources
and appearances of artifacts will be helpful but not suf-
ficient. In a research environment, peer review and
reproducibility requirements are intended to eliminate
these types of misinterpretations. However, when the
interpretation is based upon partially defined, un-codi-
fied criteria, i.e., criteria that are at least partially sub-
jective, peer review is not an efficient filter. In medical
applications, wherein missing indications in an image
can result in serious health problems and time con-
straints are important, there is an additional driving
force for indication identification without a correspon-
ding balancing criterion for artifact rejection.
Automatic image analysis would eliminate the problem
of subjective image interpretation. However, for image
analysis to be automated, both image preparation (col-
lection procedures and post collection filtering) and
image analysis criteria must be standardized and codi-
fied. This will require standards developing committees
that include users, hardware designers, and software
developers. A final caveat is that image analysis soft-
ware will detect only what has been codified.
Therefore, some images, that contain early indications
of problems that experienced human analysts might
notice, may go undetected by automated procedures.
2.3.4.2 Computer Generated Images are
Frequently Accepted as Accurate
Although Features of the Image May be
the Result of Over Processing
Problem:
Computer image improvement, for example, filter-
ing, sharpening, contrast enhancement, is based upon
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mathematical tools and assumptions that are often
poorly understood by the user. However, the ease with
which these tools can be applied can give rise to over-
processed images in which patterns, boundaries, edges,
and segregation appear but have no physical signifi-
cance. Consequently, overprocessed images give rise to
faulty conclusions based totally upon artifacts.
Approach:
There is no completely satisfactory solution to any of
the human interpretation issues. The problems can be
reduced by a combination of standardization of image
analysis procedures and education of the user to the
inherent hazards of non-rigorous image interpretation
and the creation of artifacts, including meaningless pat-
terns, through image processing and data acquisition.
2.4 Optical Coherence Tomography
Optical coherence tomography (OCT) is a three
dimensional interferometric biomedical imaging tech-
nique capable of in vivo measurements. With microme-
ter-scale spatial resolutions and penetration depths of 1-
3 mm in most tissues, OCT fills a useful niche between
confocal microscopy, which has high spatial resolution
but is difficult to implement in vivo, and ultrasound
whose spatial resolution is typically 10 to 100 times
poorer than OCT. The primary commercial use of OCT
at present is in ophthalmic applications for retinal
imaging of the human eye. However, a great deal of
research and clinical demonstrations of OCT are ongo-
ing in a variety of applications including early diagno-
sis of arterial plaques, assessment of burn severity,
detection of cancer and its precursors, and Doppler
measurements of blood flow to name a few.
First demonstrated in 1991 by Fujimoto and collabo-
rators [28], OCT is a relatively new technology with
significant promise for growth and new applications.
The focus of improvements to OCT has been on
increasing measurement speed through improved sig-
nal to noise ratios, improving spatial resolution, and
developing new measurement modalities such as phase
or polarization sensitivity to increase contrast and
broaden the diagnostic capabilities. To fully exploit the
potential of OCT as a biomedical imaging tool, sup-
porting measurement capabilities (metrology) must be
developed simultaneously. There are three significant
measurement challenges facing OCT: real time wave-
length characterization of OCT tunable laser sources,
insufficient data on optical properties of human tissues,
and the need for characterization of tissue property
changes in response to electromagnetic excitation.
Each metrology challenge and proposed technical
approaches are summarized below.
2.4.1 Wavelength Characterization of OCT
Tunable Laser Sources
Problem:
The basis of an OCT measurement is to illuminate
the specimen with a broad bandwidth of light and
coherently resolve the backscattered light to distinguish
light returning from different depths in the tissue. To do
this, the return light must be resolved either temporally
(time-domain) or spectrally (frequency-domain). The
time domain approach involves illuminating with a
spectrally broad optical source, moving the interferom-
eter’s reference mirror, and recording intensity data as
a function of reference arm delay time [29]. The fre-
quency domain approach has a fixed reference arm but
resolves the returning light by optical frequency (or
wavelength) [30]. This is generally done either with a
broadband optical source and spectrometer detection,
or with a wavelength-tunable laser source and a detec-
tor.
The frequency domain approach using a rapidly tun-
able laser (swept source) is a promising approach and is
receiving attention due to improved noise performance
and rapid measurement capability compared with time
domain approaches. The signal-to-noise ratio (SNR) of
frequency domain approaches can be significantly bet-
ter than for the time domain with theoretical sensitivity
improvements of 20-30 dB [30]. Improved measure-
ment speed of frequency domain approaches comes
from this improved sensitivity, which reduces required
sampling time, and from the elimination of the need for
the relatively slow mechanical motion of the reference
mirror in the time domain. Swept-wavelength lasers
have demonstrated sweep rates up to 290 kHz (145 nm
range) and OCT measurements have been performed
with line scan rates of up to 58 kHz [31].
Characterization of fast-swept sources involves
dynamic measurements of absolute wavelength, sweep
linearity, and instantaneous linewidth. Due to the
Fourier transform relationship, the effective depth
range goes like π/2δk where δk is the wavenumber
spacing between samples of the sweeping laser [30].
This means that poor wavelength resolution can limit
the penetration depth of the OCT. Also of practical
measurement interest is the limited reliability of current
swept wavelength laser sources. Due to the exacting
mechanical requirements on most swept sources they
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tend to drift out of specification in terms of their sweep
repeatability and linearity. Therefore, for higher accura-
cy applications, real time monitoring of laser wave-
length during the OCT scan is important.
Optical frequency comb sources also present an
attractive possibility as an innovative spectrometry tool
for OCT. Optical combs are based on a pulsed laser in
a resonant cavity operating in a highly nonlinear regime
to generate harmonics. Such sources yield spectra con-
sisting of narrow lines evenly spaced in optical fre-
quency and covering bandwidths of 1 to 2 µm [32]. In
both the optical comb source and the swept laser
source, it is notable that the instantaneous linewidth of
the laser or a single comb tooth is a very small fraction
of the total bandwidth range. The spectral range deter-
mines the spatial resolution of the measurement and the
spectral resolution specifies the maximum depth range.
However, since depth range is generally limited in
practice by the SNR, swept laser or comb-based OCT
sources are capable of providing narrower linewidths
than are currently needed. Therefore, it may be advan-
tageous to use these narrow-linewidth sources to spec-
trally encode information to improve noise averaging
or measurement efficiency. This prompts the consider-
ation of source bandwidth efficiency.
Approach:
Perform accurate characterizations of OCT source
wavelength, sweep linearity, and linewidth at video
rates. Improved metrology in wavelength characteriza-
tion (and stability) could allow multiplexing of infor-
mation onto the same optical bandwidth to improve the
information or noise reduction content of the signal in
a given optical bandwidth. Technology exists for the
real-time monitoring of swept laser linewidth. However
it is not widely available and is often too slow to be of
use to video rate swept laser OCT systems.
2.4.2 Insufficient Data on Optical Properties of
Human Tissues
Problem:
To fully describe the propagation of light in tissue
requires knowledge of the full spatial and spectral
dependence of the tissue’s complex refractive index. As
a comparison, in the field of non-biological optics, light
is refracted and guided through lenses, mirrors, wave-
guides, etc. A key parameter to describe light’s behav-
ior in any material is the complex refractive index (gov-
erning propagation and loss). Extensive data on the
refractive indices of optical glasses are published to
high accuracy. In contrast, for biophotonic diagnostics,
the propagation medium for light is tissue where the
‘database’ of tissue refractive index is sparsely populat-
ed. This results in two limitations. First, propagation of
light through tissue is more difficult to predict. This is
not limited to OCT, but to any instrumentation where
light is to be delivered to a particular portion of tissue
(including both diagnostic and therapeutic applica-
tions). Second, diagnostic techniques ultimately meas-
ure local variations in refractive index in order to deter-
mine tissue health. Interferometric techniques such as
OCT are especially susceptible to small (nanometer
scale, in the case of phase sensitive OCT) variations in
the optical pathlength experienced by the backscattered
photons. A trusted database of human tissue refractive
indices will be an important milestone that enables a
significant jump in the diagnostic capabilities of OCT
and other biophotonic techniques.
The task of characterizing human tissue refractive
index is a huge undertaking. Unlike optical-quality
glasses, most tissue is highly heterogeneous. For exam-
ple, in the retinal nerve fiber layer of the human eye,
the size scale of various constituents ranges over 3
orders of magnitude with neurotubules (25 nm), mito-
chondria (1 µm), and cell bodies (10 µm). Tissue also
experiences significant anisotropies in its structure
resulting in polarization-dependent variations in the
complex refractive index such as birefringence and
diattenuation.
Approach:
To create a database of the various constituents of
human tissue for refractive index as a function of wave-
length. Of course, to be useful, this data would have to
be combined with an understanding of the relationship
between tissue properties and measured refractive
index. In other words, the measurement uncertainty
will depend on the sample-to-sample variability of
refractive index. This will involve some characteriza-
tion of the tissue with regard to its health. Finally, the
characterization of tissue index will need to be applied
to modeling to yield predictions of the coherent proper-
ties of light as it is backscattered from the various tis-
sue types. Because of the complexity of the problem, a
panel of experts should rank order the priority for
acquiring the information to populate this database.
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2.4.3 The Need for Characterization of Tissue
Property Changes in Response to
Electromagnetic Excitation
Problem:
The dielectric susceptibility of a medium describes
the intrinsic properties affecting electromagnetic prop-
agation through that medium. This includes the previ-
ous discussion of the effect of the complex refractive
index on propagating light. On the other side of this
interaction is the effect that electromagnetic fields have
on the tissue as they propagate. This property of the tis-
sue’s “electromagnetic response” is important to both
the understanding of the health and function of the tis-
sue as well as to determine how light will propagate
during a photonic diagnostic or therapeutic procedure.
One example is in the electromagnetic excitation
(action potential) of neural tissue (axons). An electro-
magnetic pulse from the brain instigates physical
changes in the nerve including motion of the axon
which is detectable through phase-sensitive OCT.
Development and characterization of OCT-based meas-
urement strategies to probe tissue electromagnetic
response will be important to fundamental understand-
ing of tissue function and its related pathology.
Characterization of light propagation in tissue modi-
fied by its “electromagnetic response” is particularly
important for understanding tissue response to laser
stimulation. For example, laser-induced heating of tis-
sue can produce deformations of the tissue (thermo-
elastic effects) and changes in the refractive index
(thermo-refractive effects). Both of these effects will
modify the propagation character of the applied laser
light depending on laser wavelength and power.
Understanding these properties is necessary to properly
characterize the propagation of light during photonic
diagnostics (to invert measurement results to yield tis-
sue properties) or during therapeutic applications (to
direct and localize the applied light).
Approach:
Develop measurement techniques for assessing
nanometer scale response of tissue to electromagnetic
stimuli. Characterize the propagation parameters of tis-
sue in response to the applied fields of the light source
3. Summary
This manuscript focuses on four major areas of clin-
ical applications of biophotonics at both the macro-
scopic and microscopic scales: microarray technology
for assays of DNA and proteins, flow cytometry tech-
nology for measurements of antigens on the surface of
a cell, optical imaging for in vitro diagnostics of patho-
logical tissue conditions, and optical coherence tomog-
raphy for in vivo imaging and diagnostics. There are
other optical probing methodologies, such as laser-
induced stimulation and vibrational spectroscopy,
under development and it is likely that some of them
will find applications in the clinic. However, the pur-
pose of this paper is to focus on the critical measure-
ment needs for tissue and cell diagnostics. The field of
biophotonics is developing rapidly and its symbiotic
relation with nanotechnology through improved artifi-
cial markers such as quantum dots and nanocrystals, is
expected to have increasing impact on the quality of
health care. Progress will depend on identification of
technological obstacles and the development of solu-
tions to these obstacles.
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